Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Clin Cancer Res. 2018 Jun 5;24(19):4734–4744. doi: 10.1158/1078-0432.CCR-17-1523

Figure 2. Proportion of early grade 3 hypertension in bevacizumab-treated patients stratified by top SLC29A1-HSP90AB1 SNP carrier status.

Figure 2

Variant alleles of each SNP are associated with higher incidence of early grade 3 hypertension (HTN) in analyzed subjects. Fractions represent the number of HTN cases over the total number of subjects for each carrier status.